Home/Pipeline/MCLA-145

MCLA-145

Solid Tumors

Phase 1/2Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Merus

About Merus

Merus is a clinical-stage biotech focused on closing in on cancer by discovering and developing novel multispecific antibody therapeutics. The company's core asset is its proprietary Multiclonics® platform, which enables the creation of full-length, human IgG bispecific and trispecific antibodies with manufacturing and pharmacokinetic profiles akin to conventional monoclonal antibodies. Merus has built a robust, wholly-owned and partnered clinical pipeline, with its lead candidate, petosemtamab, in Phase 3 development for head and neck cancer. The company's recent acquisition by and integration into Genmab represents a pivotal strategic shift, providing enhanced resources and a broader platform to accelerate its ambitious oncology programs.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active